NewAmsterdam Pharma Company N.V NAMS

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
44/100
Developing

Ranked against 712 peers in Biotechnology

About NewAmsterdam Pharma Company N.V

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is … Full NAMS analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.72), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.37), raising refinancing risk.
  • Inconsistent Cash Generation Cash generation is inconsistent (score 0.45), indicating operational challenges.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
38
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where NAMS ranks in Biotechnology

NewAmsterdam Pharma Company N.V ranks #328 of 713 scored companies in Biotechnology by moat score — the top 46%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
324 Viridian Therapeutics, Inc. VRDN 44/100 Developing
325 Wave Life Sciences Ltd. WVE 44/100 Developing
326 Cyclacel Pharmaceuticals, Inc. CYCC 44/100 Developing
327 Cyclacel Pharmaceuticals, Inc. CYCCP 44/100 Developing
328 NewAmsterdam Pharma Company N.V NAMS 44/100 Developing
329 Abpro Holdings, Inc. ABPWW 44/100 Developing
330 Aura Biosciences, Inc. AURA 43/100 Developing
331 Affimed N.V. AFMD 43/100 Developing
332 Annexon, Inc. ANNX 43/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How NAMS scores on the Corporate Default defenses

Pricing Power

Score 38 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 39 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 45 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 48 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 49 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 43 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding NAMS's moat

What is NewAmsterdam Pharma Company N.V's moat score?

NewAmsterdam Pharma Company N.V (NAMS) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #328 of 713 scored companies in Biotechnology, the top 46%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (49/100) and its weakest is Pricing Power (38/100).

How does NewAmsterdam Pharma Company N.V compare with other Biotechnology companies?

NewAmsterdam Pharma Company N.V ranks #328 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Cyclacel Pharmaceuticals, Inc. (CYCCP) at 44 just above it and Abpro Holdings, Inc. (ABPWW) at 44 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is NewAmsterdam Pharma Company N.V scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for NewAmsterdam Pharma Company N.V?

The Corporate Default template measures 6 defenses, and NAMS scores: Pricing Power (38), Cost Advantage (39), Customer Stickiness (45), Capital Efficiency (48), Resilience (49), Scale & Market Position (43). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000